[Neurology and psychiatry].

Munchener medizinische Wochenschrift Pub Date : 1951-01-01 DOI:10.1097/00000441-193411000-00052

M. Kaess

{"title":"[Neurology and psychiatry].","authors":"M. Kaess","doi":"10.1097/00000441-193411000-00052","DOIUrl":null,"url":null,"abstract":"1 Britton KE, Granowska M. Tumour identification using radiopharmaceuticals. Clin Radiol 1997;52:731–8. 2 Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin N Am 1996;25:93–113. 3 Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995;25:76–91. 4 Krasnow AZ, Hellman RS, Timins ME, Collier BD, et al. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107–41. 5 Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med 1998;42:43–8. 6 Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60–71. 7 Chin BB, Zukerberg BW, Buchpiguel C, Alavi A. Thallium-201 uptake in lung cancer. J Nucl Med 1995;36:1514–9. 8 Conti PS, Lilien DL, Hawley K, Keppler J, et al. PET and {18F}-FDG in oncology: a clinical update. Nucl Med Biol 1996;23: 717–35. 9 Cook GJ, Maisey MN. The current status of clin ica l PET imaging. Clin Radiol 1996;51:603–13. 10 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737–43. 11 Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997;27: 40–54. 12 Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–37. 13 Goldenberg DM. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer 1997;80 (Suppl 12): 2431–5. 14 Bader M, Koppenhagen K. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Rec Result Cancer Res 1996;142: 137–62. 15 Critchley M. Octreotide scanning for carcinoid tumours. Postgrad Med J 1997; 73:399–402. 16 Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med 1995; 39:(Suppl 1):3–8. 17 Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1–7. 18 Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun 1997;18:698–709. 19 Alazraki NP, Eshima D, Eshima LA, Herda SC, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55–67. 20 North JH Jr, Spellman JE. Role of sentinel node biopsy in the management of malignant melanoma. Oncology 1996;10: 1237–42.","PeriodicalId":18963,"journal":{"name":"Munchener medizinische Wochenschrift","volume":"5 1","pages":"1281-5"},"PeriodicalIF":0.0000,"publicationDate":"1951-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Munchener medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00000441-193411000-00052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

1 Britton KE, Granowska M. Tumour identification using radiopharmaceuticals. Clin Radiol 1997;52:731–8. 2 Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin N Am 1996;25:93–113. 3 Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995;25:76–91. 4 Krasnow AZ, Hellman RS, Timins ME, Collier BD, et al. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107–41. 5 Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med 1998;42:43–8. 6 Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60–71. 7 Chin BB, Zukerberg BW, Buchpiguel C, Alavi A. Thallium-201 uptake in lung cancer. J Nucl Med 1995;36:1514–9. 8 Conti PS, Lilien DL, Hawley K, Keppler J, et al. PET and {18F}-FDG in oncology: a clinical update. Nucl Med Biol 1996;23: 717–35. 9 Cook GJ, Maisey MN. The current status of clin ica l PET imaging. Clin Radiol 1996;51:603–13. 10 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737–43. 11 Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997;27: 40–54. 12 Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–37. 13 Goldenberg DM. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer 1997;80 (Suppl 12): 2431–5. 14 Bader M, Koppenhagen K. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Rec Result Cancer Res 1996;142: 137–62. 15 Critchley M. Octreotide scanning for carcinoid tumours. Postgrad Med J 1997; 73:399–402. 16 Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med 1995; 39:(Suppl 1):3–8. 17 Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1–7. 18 Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun 1997;18:698–709. 19 Alazraki NP, Eshima D, Eshima LA, Herda SC, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55–67. 20 North JH Jr, Spellman JE. Role of sentinel node biopsy in the management of malignant melanoma. Oncology 1996;10: 1237–42.

查看原文本刊更多论文

[神经病学和精神病学]。

[1]王晓明，王晓明，王晓明，等。放射性药物在肿瘤诊断中的应用。中华放射医学杂志1997;52:731-8。2加洛威RJ，斯莫里奇RC。甲状腺癌的影像学检查。中西医结合杂志1996;25(1):93 - 93。骨扫描:我们现在在哪里?中华核医学杂志1995;25:76-91。[4]刘建军，刘建军，李建军，等。肿瘤学诊断骨扫描。中华核医学杂志1997;27:107-41。[5]张丽娟。骨显像在乳腺癌治疗中的应用。[J]中华核医学杂志1998;42(2):43 - 43。[6]李晓东，李晓东，李晓东，等。Ga-67显像在评价淋巴瘤患者治疗效果中的作用。半核医学1995;25:60-71。[7]张建军，张建军，张建军，等。肺癌患者体内铊-201的摄取。[J]中华核医学杂志1995;36:1514 - 919。[8]李建军，李建军，李建军，等。PET和{18F}-FDG在肿瘤学中的临床进展核医学杂志1996;23:717-35。9 Cook GJ, Maisey MN。PET成像的临床应用现状。中华放射医学杂志1996;51:603-13。[10]张建军，张建军，张建军，等。PET显像在临床肿瘤学中的应用价值。核医学，1996;23:37 - 43。公元11韦克斯曼(99m)Tc甲氧基异丁基异腈在乳腺癌成像中的作用。半核医学1997;27:40-54。[12]李建军，李建军，李建军，李建军，李建军。用核医学试验测定缺氧和预测肿瘤放射抵抗。电子学报，1998;46(6):229 - 37。[13]黄晓明。放射标记抗体在肿瘤影像学中的应用前景。中国癌症杂志1997;20(增刊12):2431 - 531。[14]王晓东，王晓东，王晓东，等。生长抑素受体显像在胃肠胰神经内分泌肿瘤诊断中的应用。中华医学杂志，1996;19(2):391 - 391。15 Critchley M.奥曲肽扫描在类癌肿瘤中的应用。Postgrad Med J 1997;73:399 - 402。[16]王晓明，王晓明，王晓明，等。间碘苄基胍在神经内分泌肿瘤诊断中的应用价值。中华核医学杂志1995;39: 17(1): 3 - 8。17 .沃尔。PET在乳腺癌成像中的现状综述。中华核医学杂志1998;42:1-7。18 Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ。乳腺癌的闪烁成像:综述。核医学杂志1997;18:698-709。[19]张建军，张建军，张建军，等。淋巴显像，前哨淋巴结概念，以及术中伽玛探针在黑色素瘤，乳腺癌和其他潜在癌症中的应用。半核医学1997;27:55-67。20 North JH Jr, Spellman JE。前哨淋巴结活检在恶性黑色素瘤治疗中的作用。肿瘤学1996;10:1237-42。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Munchener medizinische Wochenschrift

自引率

0.00%

发文量